WHO Pharmaceuticals Newsletter 1998, No. 03&04
(1998; 18 pages)
Índice de contenido
Cerrar esta carpetaRegulatory actions
Ver el documentoAluminium in total parenteral nutrition - labelling requirements & warning
Ver el documentoAstemizole - warning concerning cardiovascular adverse events
Ver el documentoBromfenac - warning label: liver damage
Ver el documentoCarbamazepine - warning concerning precipitation
Ver el documentoChlormezanone - withdrawn
Ver el documentoCounterfeit drugs - warning to the public
Ver el documentoDietary supplement "Sleeping Buddha" - warning concerning estazolam content
Ver el documentoFenfluramine - withdrawn
Ver el documentoHuman dura mater (freeze-dried) - restrictive measures
Ver el documentoIsotretinoin - psychiatric adverse effects
Ver el documentoPyrithione zinc (Skin-CapR) - withdrawn
Ver el documentoSertindole - approval application withdrawn
Ver el documentoTerfenadine - additional drug interactions
Ver el documentoTerfenadine - withdrawn following approval of fexofenadine
Abrir esta carpeta y ver su contenidoDrug surveillance
Abrir esta carpeta y ver su contenidoNew developments
Ver el documentoRecent approvals
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Fenfluramine - withdrawn

United Arab Emirates. In line with international opinion, the Ministry of Health has withdrawn the marketing approval for fenfluramine (PonderaxR), the only anorectic drug approved in the UAE.

[See also Pharmaceuticals Newsletters Nos. 9&10, September&October 1997 and DRS Alert No. 63 of 16 September 1997]

Reference: UAE Ministry of Health Drug Information Bulletin 1997 No. 3, p.2.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013